News | November 08, 2013

Zevacor Molecular Awards IBA Contract to Build Only U.S. Commercial Cyclotron for Sr-82 Production

Cyclone 70 to stabilize U.S. supply of strontium 82/rubidium 82 generators for use in diagnosis of cardiovascular disease

cyclone 70 zevacor IBM nuclear imaging radiopharmaceuticals and tracers PET
November 8, 2013 — Zevacor Molecular, a healthcare firm that manufactures and distributes positron emissions tomography (PET) and single photon emission computed tomography (SPECT) radiopharmaceuticals, has purchased the first 70 MeV Cyclotron dedicated to medical use in the United States from Ion Beam Applications, S.A. (IBA).
 
The purchase of IBA’s Cyclone 70 is the first of several investments Zevacor is making to secure the future of nuclear medicine and molecular imaging. The 70 MeV Cyclotron is expected to be operational in the fall of 2016 and will help to stabilize the domestic supply of medical isotopes needed to diagnose and treat critical illnesses. 
 
Strontium 82 (Sr-82) has a half-life of about 25 days, allowing it to be easily shipped to imaging facilities for about a month of use. It is shipped as a generator unit to produce rubidium 82 (Rb-82) at the point of imaging, since Rb-82 has a half-life of only 75 seconds. The isotope is primarily used for nuclear myocardial perfusion exams.
 
In addition to the cyclotron, Zevacor will also invest in significant infrastructure to create a state-of-the-art manufacturing facility to house the Cyclone 70 as well as other cyclotrons and manufacturing equipment. It expects to determine the location by the end of 2013.
 
“This is just the beginning,” said John Zehner, executive vice president and chief operating officer, Zevacor Molecular. “With strategic investments like the purchase of the Cyclone 70, Zevacor and our partners will help hospitals improve the diagnosis and treatment of cancer, cardiovascular disease and other critical illnesses. Our goal is to support the current needs of the nuclear medicine and molecular imaging community and assist in the growth and development of new diagnostics and therapeutics.”
 
The main focus of the first 70 MeV Cyclotron will be to commercially manufacture Sr-82 to ensure ample, stable, U.S.-based supply of Sr-82/Rb-82 generators for use in the diagnosis of cardiovascular disease. This important radiotracer has no current commercial supplier and only has U.S. and foreign-based supply from national labs.
 
Although the primary focus is the manufacture of Sr-82, the Cyclone 70 is capable of producing a wide variety of other radionuclides for both research and clinical applications. 
 
For more information: www.zevacor.com, www.iba-worldwide.com

Related Content

NIH Study of Brain Energy Patterns Provides New Insights into Alcohol Effects

NIH scientists present a new method for combining measures of brain activity (left) and glucose consumption (right) to study regional specialization and to better understand the effects of alcohol on the human brain. Image courtesy of Ehsan Shokri-Kojori, Ph.D., of NIAAA.

News | Neuro Imaging | March 22, 2019
March 22, 2019 — Assessing the patterns of energy use and neuronal activity simultaneously in the human brain improve
Improving Molecular Imaging Using a Deep Learning Approach
News | Nuclear Imaging | March 21, 2019
Generating comprehensive molecular images of organs and tumors in living organisms can be performed at ultra-fast speed...
PET Scans Show Biomarkers Could Spare Some Breast Cancer Patients from Chemotherapy
News | PET Imaging | March 18, 2019
A new study positron emission tomography (PET) scans has identified a biomarker that may accurately predict which...
Researchers Create New Method for Developing Cancer Imaging Isotopes

Prototype fluidic system for zirconium-89 purification. Image taken through a hot cell window at the Department of Radiology, University of Washington. Image courtesy of Matthew O’Hara, Pacific Northwest National Laboratory

News | Radiopharmaceuticals and Tracers | March 14, 2019
A team of researchers at the University of Washington announced they developed a new automated system for producing...
Siemens Healthineers Announces First U.S. Install of Biograph Vision PET/CT
News | PET-CT | March 06, 2019
Siemens Healthineers’ new Biograph Vision positron emission tomography/computed tomography (PET/CT) system has been...
ImaginAb Enrolls First Patient in Phase II PET Agent Clinical Trial
News | Radiopharmaceuticals and Tracers | January 30, 2019
ImaginAb Inc. announced the enrollment of the first patient in the Phase II clinical trial of the company’s CD8+ T Cell...
FDA Clears United Imaging Healthcare uExplorer Total-Body Scanner
Technology | PET-CT | January 23, 2019
January 23, 2019 — United Imaging Healthcare (United Imaging) announced U.S.
MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Videos | SPECT-CT | December 12, 2018
This is a walk around of the new Spectrum Dynamics Veriton SPECT-CT nuclear imaging system introduced at the 2018 ...